公开(公告)号：US20240335478A1

公开(公告)日：2024-10-10

申请号：US18288241

申请日：2022-04-22

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： SHAFIQUE KESHAVJEE ,  MARCELO CYPEL ,  MINGYAO LIU ,  STEPHEN JUVET ,  KUMI MESAKI

IPC: A61K35/42 ,  A61K31/52 ,  A61K31/573 ,  A61K38/13 ,  A61P37/06 ,  C07K14/47 ,  C07K14/54 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC classification number: A61K35/42 ,  A61K31/52 ,  A61K31/573 ,  A61K38/13 ,  A61P37/06 ,  C07K14/4703 ,  C07K14/5428 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N2310/20

Abstract: The present disclosure relates generally to epigenetically and genetically modified organs and tissues and methods of producing same. In particular, the present disclosure is directed to organs and tissues that have been epigenetically and/or genetically modified at one or multiple loci to control inflammation-regulating or immune-regulating gene expression and thereby improve the condition of the organs and tissues.

公开(公告)号：US20200241004A1

公开(公告)日：2020-07-30

申请号：US16635012

申请日：2018-07-30

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： SHAFIQUE KESHAVJEE ,  MINGYAO LIU ,  MARCELO CYPEL ,  ANDREW SAGE

IPC: G01N33/68

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of one or more biomarkers selected from IL-6, IL-8, sTNFR1 and sTREM-1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of one or more biomarkers selected from IL-8, IL-6, sTNFR1 and sTREM-1; and iii. a) comparing the polypeptide level of the one or more biomarkers in the perfusate sample with a control or cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the polypeptide level of one or several of the one or more biomarkers in combination, as part of an algebraic calculation of outcome/risk.